Alerts will be sent to your verified email
Verify Email
BLISSGVS
|
Bliss GVS Pharma
|
Beta Drugs
|
Syncom Formulations
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
R&D as a % of Total Sales
|
2.57 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
7.87 % | 21.73 % | 8.81 % |
|
5yr average Equity Multiplier
|
1.33 | 1.75 | 1.5 |
|
5yr Average Asset Turnover Ratio
|
0.63 | 1.04 | 0.79 |
|
5yr Avg Net Profit Margin
|
9.44 % | 11.97 % | 7.78 % |
|
Price to Book
|
1.56 | 0.0 | 5.25 |
|
P/E
|
19.48 | 41.27 | 36.34 |
|
5yr Avg Cash Conversion Cycle
|
169.17 Days | 15.7 Days | 84.02 Days |
|
Inventory Days
|
51.37 Days | 43.83 Days | 27.61 Days |
|
Days Receivable
|
187.07 Days | 87.61 Days | 123.89 Days |
|
Days Payable
|
75.42 Days | 113.94 Days | 93.18 Days |
|
5yr Average Interest Coverage Ratio
|
15.0 | 13.71 | 39.83 |
|
5yr Avg ROCE
|
14.67 % | 27.85 % | 12.74 % |
|
5yr Avg Operating Profit Margin
|
17.43 % | 21.58 % | 9.47 % |
|
5 yr average Debt to Equity
|
0.13 | 0.23 | 0.2 |
|
5yr CAGR Net Profit
|
-4.95 % | 31.07 % | 19.56 % |
|
5yr Average Return on Assets
|
5.91 % | 12.53 % | 5.89 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
35.29 % | 66.73 % | 50.57 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
2.15 % | 0.02 % | 4.45 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Bliss GVS Pharma
|
Beta Drugs
|
Syncom Formulations
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|